Abstract 400P
Background
Breast cancer is the leading killer of female cancer patient. Lung cancer became the second affecting cancer (12%) but the main killer (25%) in female cancer patient. (Cancer fact and Figures 2017” report published by American Cancer Society) and odd of getting lung cancer are 1 in 17. In Bangladesh, the status and features of female lung cancer is not clear. In western country, female are more prone to lung cancer due to some risk factor like smoking, alcohol, exposure of radon etc than Bangladesh. We tried to find out the socio-demographic status and clinical features of lung cancer of female in Bangladesh.
Methods
This was a descriptive comparative observational study on 2396 female cancer patients reached at Outpatient of Medical oncology department of National Institute of cancer Research and Hospital, Mohakhali, Bangladesh from January 2018 to December 2018. Patients were selected purposive sampling method.
Results
Total number of 2396 female patients were included in this study. The average age of female lung cancer patient was 56.12 years and average weight was 45.32kg. We had found 336 lung cancer patients (14%) among the 2396 female cancer patient. 58% were adenocarcinoma, 26% were Squamous Cell, 7% small cell variety with undifferentiated and others like Sarcoma, mesothelioma etc were 9%. Most of the patients were illiterate (59%) and 79% patient were poor or below average economically. 42% female patient didn’t have any habitual problem. 46.82%% patients had the battle nut/ Jarda, 7.65% were smoker, about 10% had more than one habitual issue. At the time of presentation none of the had ECOG 0, patients had performance status O, most of the patient’s performance status (ECOG) were 1 (58%) ECOG2 were 27%. 39% patient had comorbidity, among them most frequent comorbidity was Hypertension which was 39% and second was DM (33%) and 20% patient having more than one comorbidity.
Conclusions
The percentage of female lung cancer in Bangladesh is pretty high among female cancer patient. female are most vulnerable group in rural area as well as they need special attention. Moreover, female lung cancer with other comorbidities makes the treatment more complicated for the cancer physician as well as brings the worst outcome. So, female lung cancer management should be personalized and comprehensive.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract
206P - Population-based validation of the risk stratification among prostate cancer patients
Presenter: Mu Xie
Session: Poster display session
Resources:
Abstract
211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
Presenter: Chi Fai Ng
Session: Poster display session
Resources:
Abstract
212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice
Presenter: Amit Rauthan
Session: Poster display session
Resources:
Abstract
213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre
Presenter: Ravindran Kanesvaran
Session: Poster display session
Resources:
Abstract
214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib
Presenter: Revati Sharma
Session: Poster display session
Resources:
Abstract
215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications
Presenter: Shanky Singh
Session: Poster display session
Resources:
Abstract
216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour
Presenter: Mira Mostafa
Session: Poster display session
Resources:
Abstract
217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab
Presenter: Koichiro Ogihara
Session: Poster display session
Resources:
Abstract
219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients
Presenter: Amanda Dania Satiti
Session: Poster display session
Resources:
Abstract